Australija - anglų - Department of Health (Therapeutic Goods Administration)

axpo pty ltd - nigella sativa, quantity: 500 mg - capsule, soft - excipient ingredients: hydroxypropyl starch; purified water; glycerol - maintain/support general health and wellbeing ; helps maintain/support healthy cholesterol ; helps maintain/support healthy blood sugar/glucose ; maintain/support cardiovascular system health ; maintain/support healthy immune system function ; decrease/reduce/relieve symptoms of common cold ; maintain/support skin health

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

bausch & lomb incorporated - hydroxypropyl cellulose (1600000 wamw) (unii: rfw2et671p) (hydroxypropyl cellulose (1600000 wamw) - unii:rfw2et671p) - hydroxypropyl cellulose (type h) 5 mg - lacrisert is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. lacrisert is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. lacrisert is also indicated for patients with: lacrisert is contraindicated in patients who are hypersensitive to hydroxypropyl cellulose. clinical experience with lacrisert indicates that in some patients several weeks may be required before satisfactory improvement of symptoms is achieved. two applicators (one spare) are supplied with each package. preparing to insert lacrisert before opening the package of lacrisert, wash your hands thoroughly with soap and water. step 1: on a flat surface, open blister pocket slowly and smoothly by peeling back label area. each blister pocket contains one lacrisert ophthalmic insert. step 2: open applicator package with label side up. avoid touching grooved tip of the applicator. pick up applicator by the wide end and rinse the tip thoroughly under hot running tap water. gently shake off excess water. step 3: hold applicator with tip facing down and with forefinger on top to guide and apply gentle pressure. lightly press the grooved tip of the applicator onto the lacrisert ophthalmic insert and it will adhere to the applicator. it is important to follow steps 4 and 5 carefully or you might experience difficulty in keeping lacrisert (hydroxypropyl cellulose ophthalmic insert) in your eye. step 4: look into a mirror. starting with the right eye, turn your head to the right so that the colored part of the eye is close to your nose. use your free hand to grasp the lower lid between the thumb and index finger. pull the lid away from the eyeball and create a pocket between the white part of the eyeball and the lid. step 5: place the tip of the applicator containing lacrisert into the pocket. avoid touching the colored part of the eye. remove the applicator. it is important, after removing the applicator, to look down, then release the lower eyelid. lacrisert (hydroxypropyl cellulose ophthalmic insert) should remain deep in the lower pocket recess of the eye and not near the edge of the lower eyelid. repeat procedure with left eye, turning head to the left so that the colored part of the eye is close to your nose. rinse the applicator thoroughly under hot running tap water after use. gently shake off visible water droplets and promptly return it to the storage container. note that the storage container provides space for a strip of two lacrisert ophthalmic inserts next to the applicator storage compartment. important if lacrisert causes worsening of symptoms, or if new symptoms develop, it should be removed and your prescriber contacted. should the removal of the lacrisert ophthalmic insert be necessary, follow these instructions. caution: because this product may produce transient blurring of vision, you should exercise caution when operating hazardous machinery or driving a motor vehicle. store below 86°f (30°c) distributed by: bausch + lomb, a division of bausch health us, llc bridgewater, nj 08807 usa manufactured by: renaissance lakewood, llc, lakewood, nj 08701 usa this instructions for use has been approved by the u.s. food and drug administration. lacrisert is a trademark of bausch & lomb incorporated or its affiliates. © 2019 bausch & lomb incorporated or its affiliates 9421304 revised: 10/2019

Izraelis - anglų - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - azithromycin as dihydrate - capsules - azithromycin as dihydrate 250 mg - azithromycin - azithromycin - infections caused by susceptible organisms in lower respiratory tract including bronchitis and pneumonia, skin and soft tissue infections, otitis media, upper respiratory tract infections including sinusitis and pharyngitis, tonsilitis, also in the treatment of uncomplicated genital infections due to chlamydia trachomatis.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - larotrectinib sulfate, quantity: 30.7 mg - capsule, hard - excipient ingredients: gelatin; propylene glycol; dimethicone 12500; brilliant blue fcf aluminium lake; titanium dioxide; shellac; strong ammonia solution - vitrakvi (larotrectinib) has provisional approval in australia for the treatment of adult and paediatric patients with locally advanced or metastatic solid tumours that:,? have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion without a known acquired resistance mutation, ? are metastatic or where surgical resection is likely to result in severe morbidity, and ? have either progressed following treatment or who have no satisfactory alternative therapy. the decision to approve this indication has been made on the basis of objective response rate (orr) and duration of response from single arm clinical studies. the sponsor is required to submit further clinical data to confirm the clinical benefit of the medicine.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - larotrectinib sulfate, quantity: 122.9 mg - capsule, hard - excipient ingredients: titanium dioxide; shellac; gelatin; dimethicone 12500; propylene glycol; brilliant blue fcf aluminium lake; strong ammonia solution - vitrakvi (larotrectinib) has provisional approval in australia for the treatment of adult and paediatric patients with locally advanced or metastatic solid tumours that:,? have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion without a known acquired resistance mutation, ? are metastatic or where surgical resection is likely to result in severe morbidity, and ? have either progressed following treatment or who have no satisfactory alternative therapy. the decision to approve this indication has been made on the basis of objective response rate (orr) and duration of response from single arm clinical studies. the sponsor is required to submit further clinical data to confirm the clinical benefit of the medicine.

Singapūras - anglų - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - dabigatran etexilate mesilate 126.83 mg eqv dabigatran etexilate - capsule - 110 mg - dabigatran etexilate mesilate 126.83 mg eqv dabigatran etexilate 110 mg

Singapūras - anglų - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - dabigatran etexilate mesilate 86.48mg eqv dabigatran etexilate - capsule - 75 mg - dabigatran etexilate mesilate 86.48mg eqv dabigatran etexilate 75 mg

Singapūras - anglų - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - dabigatran etexilate mesilate 172.95mg eqv dabigatran etexilate - capsule - 150.00mg - dabigatran etexilate mesilate 172.95mg eqv dabigatran etexilate 150.00mg

Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

boehringer ingelheim ltd - dabigatran etexilate mesilate - capsule - 75mg

Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

boehringer ingelheim ltd - dabigatran etexilate mesilate - capsule - 110mg